Printer Friendly

SCIOS NOVA INITIATES PHASE I/II CLINICAL STUDIES OF NATRECOR(TM) hBNP IN HEART FAILURE PATIENTS

 MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire/ -- Scios Nova Inc. (NASDAQ-NMS: SCIO) today announced that it has begun Phase I/II clinical studies of NATRECOR(TM) human brain natriuretic peptide (hBNP) which is being developed for the treatment of acute congestive heart failure. The Phase I/II studies will include 40 to 60 patients and will be conducted at several centers in the United States.
 In November 1993, Scios Nova submitted an investigational new drug (IND) application to the Food and Drug Administration seeking clearance to commence clinical studies of NATRECOR hBNP.
 "Scios Nova's product development strategy is to focus on medications that address acute illnesses," said Richard L. Casey, Scios Nova chairman and chief executive officer. "We are pleased that NATRECOR hBNP, the company's second acute-care therapeutic, has entered the clinical investigation phase." Scios Nova's lead acute-care product, AURICULIN(R) ANP, is in a 500-patient Phase III clinical trial for the treatment of acute kidney failure.
 Human BNP, which was discovered by Scios Nova scientists, is a naturally occurring hormone. BNP is produced predominately in the ventricles of the heart. Studies show that BNP production in the heart increases dramatically in patients with congestive heart failure, indicating that BNP may be a natural corrective response to a failing heart. Research to date suggests that BNP has a number of biological effects including eliminating salt and water from the body, dilating blood vessels to improve cardiac function and decreasing the secretion of certain hormones which lead to blood vessel constriction and elevated blood pressure.
 Scios Nova holds an issued United States patent on human BNP and related compounds. Patent applications have also been filed in Europe and Japan.
 Scios Nova Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios Nova focuses its research and development efforts on the treatment of acute illnesses, primarily in the areas of cardiorenal disease and inflammation. The company is also collaborating with corporate partners in the development of basic fibroblast growth factor (bFGF), insulinotropin and therapies for Alzheimer's disease. The company's drug discovery technology encompasses both biotechnology techniques and small molecule design to develop biopharmaceutical products.
 -0- 1/12/94
 /CONTACT: Kira Bacon of Scios Nova, 415-940-6629/
 (SCIO)


CO: Scios Nova Inc. ST: California IN: MTC SU:

TM-RB -- SJ003 -- 1274 01/12/94 08:30 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:388
Previous Article:ABUNDANCE OF JOB CANDIDATES IN 1994 DOESN'T LESSEN NEED FOR DILIGENCE IN HIRING
Next Article:CHILD SUPPORT: IT'S NOT JUST BETWEEN PARENTS ANYMORE; FEDERAL LAW MANDATES PAYROLL WITHHOLDING
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters